Statin and Omega-3 Combination for Apolipoprotein-B Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for cardiovascular disease (CVD) often fail to effectively reduce multiple risk factors simultaneously due to omega-3 fatty acid deficiencies and side effects from lipid-regulating medications, with no single composition providing widespread applicability for CVD prevention.

Innovation Solution

A novel composition combining statins with a highly purified omega-3 fatty acid formulation containing a specific ratio of EPA:DHA (5.7:1 to 6.3) to enhance lipid profiles, reduce blood pressure, and lower apolipoprotein-B levels, administered orally to mitigate CVD risk factors.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If statins are used to lower cholesterol levels, then LDL cholesterol is reduced, but unwanted side effects occur that add additional health risks

Engineering Contradiction:

ImproveLDL cholesterol levelVSAvoidside effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent combines statins with omega-3 fatty acid formulations (specifically EPA and DHA in a 5.7:1 to 6.3 ratio) to create a synergistic therapy that lowers LDL cholesterol while simultaneously reducing triglycerides and providing vasodilatory effects, thereby achieving multiple benefits with a single combination product

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical formulation containing both statin molecules and omega-3 fatty acid esters in specific ratios, where the combination produces enhanced therapeutic effects compared to either component alone, including reduced APO-B levels and improved lipid profiles

Inventive Principle:

Principle #40Composite materials

2Adaptability or versatility

If lifestyle modifications are recommended for CVD prevention, then risk factors may be reduced, but patient non-compliance prevents optimal care

Engineering Contradiction:

Improvelifestyle modification effectivenessVSAvoidpatient compliance

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent provides a pharmaceutical intermediary (the combination formulation) that bridges the gap between lifestyle recommendations and actual patient behavior, offering a convenient single-dose or multi-dose medication that automatically provides the lipid-lowering and vasodilatory benefits without requiring ongoing lifestyle changes

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If omega-3 fatty acid supplementation is provided, then omega-3 deficiency is mediated, but existing formulations do not provide sustained vasodilatory effect

Engineering Contradiction:

Improveomega-3 fatty acid levelVSAvoidvasodilatory effect duration

Core Design Contradiction:

Quantity of substanceVSDuration of action of moving object

Solution Approach 1:

The patent optimizes the EPA:DHA ratio parameter to a specific range of 5.7:1 to 6.3, which has been demonstrated to produce sustained vasodilatory effects lasting at least 6 hours, whereas other ratios do not achieve this duration of action

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention focuses on providing high concentrations of specific omega-3 fatty acids (EPA and DHA) in a purified formulation with minimal other components, creating a localized therapeutic effect in the cardiovascular system that achieves sustained vasodilation without the variability of mixed fish oil formulations

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy effectively reduces serum cholesterol, triglycerides, and homocysteine levels, improves HDL:LDL ratios, and provides a sustained vasodilatory effect, addressing multiple CVD risk factors more effectively than individual components alone.

Implementation Method 1

Omega-3 fatty acids cause endothelium-dependent vasorelaxation by a mechanism that involves stimulation of nitric oxide formation through the phosphoinositide 3-kinase/protein kinase B (PI3-kinase/Akt) pathway

Methodology Applied

Scientific EffectPI3-kinase/Akt pathway activation:

Implementation Method 2

stimulation of nitric oxide formation through the phosphoinositide 3-kinase/protein kinase B (PI3-kinase/Akt) pathway leading to changes in the phosphorylation level of endothelial nitric oxide synthase

Methodology Applied

Scientific EffectNitric oxide formation:

Implementation Method 3

one or more statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase

Methodology Applied

Scientific EffectHMG-CoA reductase inhibition:

Implementation Method 4

The combination therapy effectively reduces serum cholesterol, triglycerides, and homocysteine levels, improves HDL:LDL ratios

Methodology Applied

Scientific EffectLipid metabolism modulation:

Data Source

PatentUS8951514B2Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels

Publication Date: 2015.02.10 PIVOTAL THERAPEUTICS

AI summary

A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.